Cox-2 Inhibition in Radiation-induced Oral Mucositis

Key Inclusion Criteria: * Patients who will be receiving at least 5000 centigray (cGy) radiation therapy to at least 2 of 14 pre-defined areas in the oral cavity. * Women of childbearing potential must agree to use a medically accepted form of contraception during the course of the study. Women of childbearing potential must have a documented negative pregnancy test within fourteen days of enrollment in the study. * Patient's willing and able to provide written informed consent for the study. Key Exclusion Criteria: * Patients with known hypersensitivity to celecoxib or other COX-2 inhibitors. * Patients who have experienced asthma, urticaria, or allergic-type reactions after taking salicylates (e.g. aspirin) or Non-steroidal anti-inflammatory drugs (NSAIDs). * Patients who have demonstrated allergic-type reactions to sulfonamides. * Patients with a history of gastric, esophageal, pyloric channel or duodenal ulcer disease or gastrointestinal bleeding. * Patients with a history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis) or pancreatic disease. * Patients with severe hepatic impairment. * Patients with advanced renal disease. * Patients with a significant bleeding disorder. * Patients under the age of 18 or over the age of 75. * Women who are pregnant or nursing. * Patients with a history of thromboembolic events including myocardial infarction, pulmonary embolism, deep venous thrombosis, transient ischemic attack and ischemic cerebrovascular accident (stroke). * Patients who have had coronary angioplasty, coronary artery bypass surgery or another cardiac revascularization procedure. * Patients with a history of a cardiac arrhythmia requiring anti-arrhythmic therapy, angina pectoris or congestive heart failure.